Donepezil, rivastigmine, galantamine and memantine for ...
Donepezil, rivastigmine, galantamine and memantine for ...
Donepezil, rivastigmine, galantamine and memantine for ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
TABLE 1 Estimated prevalence of AD by age in Engl<strong>and</strong> <strong>and</strong> Wales<br />
Age group (years) Population of Engl<strong>and</strong> <strong>and</strong> Wales<br />
Estimated prevalence <strong>for</strong> Engl<strong>and</strong> <strong>and</strong><br />
Wales<br />
Table 1 uses the prevalence rates <strong>for</strong> AD from the<br />
pooled estimates in the study by Lobo <strong>and</strong><br />
colleagues 9 to provide an estimate of the prevalence<br />
of AD <strong>for</strong> the population of Engl<strong>and</strong> <strong>and</strong> Wales<br />
(based on mid-2002 population estimates). 20 This<br />
shows that there are approximately 290,000<br />
people in Engl<strong>and</strong> <strong>and</strong> Wales with AD. Assuming<br />
that 50–64% of people with AD have the mild to<br />
moderate <strong>for</strong>m of the disease we would expect to<br />
find between 145,000 <strong>and</strong> 185,600 cases of mild to<br />
moderate disease.<br />
Estimated prevalence <strong>for</strong> primary care<br />
trust<br />
Table 2 uses the same prevalence rates <strong>for</strong> AD as<br />
above to provide an estimate of the prevalence of<br />
AD <strong>for</strong> an average population of a primary care<br />
trust (PCT). A PCT with a population of 200,000<br />
might expect to have approximately 30,000 people<br />
over the age of 65 years <strong>and</strong> approximately 1100<br />
cases of AD. It can also be seen in Table 2 that,<br />
assuming that 50–64% of people with AD have the<br />
Health Technology Assessment 2006; Vol. 10: No. 1<br />
Males Females Prevalence of AD Estimated prevalence<br />
(rate/100 people) of AD<br />
© Queen’s Printer <strong>and</strong> Controller of HMSO 2006. All rights reserved.<br />
Male Female Males Females<br />
65–69 1,116,000 1,199,000 0.6 0.7 6,696 8,393<br />
70–74 950,000 1,126,000 1.5 2.3 14,250 25,898<br />
75–79 731,000 999,000 1.8 4.3 13,158 42,957<br />
80–84 470,000 786,000 6.3 8.4 29,610 66,024<br />
85–89 204,000 458,000 8.8 14.2 17,952 65,036<br />
Total 65+ 81,666 208,308<br />
Based on population data from mid-2002 estimates.<br />
TABLE 2 Estimated prevalence of AD by age <strong>for</strong> a st<strong>and</strong>ard PCT<br />
Age group (years) St<strong>and</strong>ard PCT (200,000 people)<br />
Population Prevalence of AD Estimated Estimated prevalence<br />
(rate/100 people) prevalence of AD of mild to moderate AD<br />
Male Female<br />
65–69 8822 0.6 0.7 58 29–37<br />
70–74 7911 1.5 2.3 153 76–98<br />
75–79 6593 1.8 4.3 213 106–136<br />
80–84 4786 6.3 8.4 364 182–233<br />
85–89 1823 8.8 14.2 316 158–202<br />
Total 65+ 1104 551–706<br />
mild to moderate <strong>for</strong>m of the disease, a PCT<br />
might expect to have between 551 <strong>and</strong> 706 cases<br />
of mild to moderate disease.<br />
Incidence<br />
The 1-year incidence of all-cause dementia<br />
increases from 0.01 per 1000 population at<br />
65 years to 80 per 1000 at age 85 years. 3 The<br />
incidence of AD appears to have been stable over<br />
the past two decades, although demographic<br />
changes (e.g. ageing population) may result in an<br />
increase in prevalence in the future. 16 Incidence<br />
rates <strong>for</strong> AD in those aged over 65 years from<br />
recent studies range from 4.9 per 1000 personyears<br />
21 in a UK study; 6.55 [95% confidence<br />
interval (CI) 4.92 to 8.17] per 1000 person-years<br />
in an Italian study; 22 <strong>and</strong> 14.26 (95% CI: 12.2 to<br />
16.7) 23 in a US study.<br />
Age-related incidence<br />
A recent pooled estimate from eight European<br />
population-based studies of persons aged<br />
≥ 65 years demonstrated rising incidence rates<br />
with increasing age. 24 The age-specific incidence<br />
5